Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benvitimod cream retreatment study in mild to moderate psoriasis vulgaris
ChiCTR2200059396Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tapinarof in plaque psoriasis (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: PASI 75 response rate at week 12 after retreatment. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tapinarof
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2200059396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059396.